Drugs / RiMO-401
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06182579 | Feb 2024 → Jun 2025 | neoplasm | Coordination Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RiMO-401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06182579 ↗ |